• Deutsch
Login
Hochschule Bonn-Rhein-Sieg

Open Access

  • Home
  • Search
  • Browse
  • Publish
  • Help

Refine

Year of publication

  • 2005 (1) (remove)

1 search hit

  • 1 to 1
  • 10
  • 20
  • 50
  • 100
Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas (2005)
Jäger, Richard ; Hahne, Jens ; Jacob, Andrea ; Egert, Angela ; Schenkel, Johannes ; Wernert, Nicolas ; Schorle, Hubert ; Wellmann, Axel
BACKGROUND The t(2;5)(p23;q35) translocation is associated with a high percentage of anaplastic large-cell lymphomas (ALCL) of T- or null-cell phenotype. The translocation produces an 80 kDa hyperphosphorylated chimeric protein (p80) derived from the fusion of the anaplastic lymphoma kinase (ALK) with nucleophosmin (NPM). The NPM-ALK chimeric protein is an activated tyrosine kinase that has been shown to be a potent oncogene and presumably plays a causative role in lymphomagenesis. MATERIALS AND METHODS A transgenic mouse line was generated, where the human NPM-ALK cDNA is driven by the lck promoter conferring transgene expression to early T-cells. RESULTS Mice rapidly developed large cell lymphoblastic lymphomas with a median latency of 8 weeks, primarily involving the thymus, with lymph node as well as histologically evident extranodal organ infiltration by large tumor cells. CONCLUSION The transgenic approach described provides direct evidence for the strong transforming potential of NPM-ALK in T-cells and furthermore represents a system for the analysis of the oncogenic events mediated by NPM-ALK in vivo, which might be instrumental in the development of tyrosine kinase inhibitor therapies of potential clinical use.
  • 1 to 1

OPUS4 Logo

  • Contact
  • Imprint and Privacy policy (in German)
  • Sitelinks